Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + tislelizumab + raltitrexed + oxaliplatin
- Development stage
- Phase 2
- Lead developer
- Guangdong Provincial People's Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous, Hepatic Arterial Infusion
01
Overview
This investigational combination therapy is being evaluated for the treatment of advanced hepatocellular carcinoma (HCC). It consists of four active agents: lenvatinib, a multi-kinase inhibitor targeting VEGFR, FGFR, PDGFRα, RET, and KIT; tislelizumab, a humanized IgG4 monoclonal antibody that inhibits the programmed cell death protein 1 (PD-1) receptor; and the RALOX regimen, which involves hepatic arterial infusion chemotherapy (HAIC) using raltitrexed (a thymidylate synthase inhibitor) and oxaliplatin (a platinum-based DNA cross-linking agent). This triple-modality approach (targeted therapy, immunotherapy, and locoregional chemotherapy) aims to improve outcomes in patients with unresectable or advanced HCC by combining systemic and direct-to-liver treatments. The regimen is currently being studied in a Phase II trial sponsored by Guangdong Provincial People's Hospital.
- Other names
- Lenvatinib, Tislelizumab Combined with RALOX Regimen HAICLenvatinib + Tislelizumab + RALOX-HAIC
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on lenvatinib + tislelizumab + raltitrexed + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + tislelizumab + raltitrexed + oxaliplatin.